RPG Life Sciences Limited
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmintics, anti-convulsant, anti-spasmodic, etc. It also provides generics for immunosuppressant therapy; and finished dosage formulations for various therapies, which include nephrology, rheumatology, oncology, gastroenterology, cardiology, orthopedics, nutritional, diabetology, respiratory, neuropsychiatry, urology, vitamins and minerals, gastrointestinal, pain management, anti-diabetic, gynecology and pediatrics, cardiovascular, pediatrics, neurology, anti-dengue, dermatology, etc. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008. RPG Life Sciences Limited was founded in 1968 and is headquartered in Mumbai, India. RPG Life Sciences Limited is a subsidiary of Nucleus Life Trust.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Strong 5-year net profit CAGR of 24.9%
Concerns0
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 10 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ653.00 Cr | β | βΉ183.00 Cr | β | β | 34.5% | 12.2% | 108.0% |
| Mar 2024 | βΉ582.00 Cr | β | βΉ88.00 Cr | β | β | 23.5% | 13.5% | 29.4% |
| Mar 2023 | βΉ513.00 Cr | β | βΉ68.00 Cr | β | β | 22.1% | 16.6% | 33.3% |
| Mar 2022 | βΉ440.00 Cr | β | βΉ51.00 Cr | β | β | 19.9% | 13.1% | 27.5% |
| Mar 2021 | βΉ389.00 Cr | β | βΉ40.00 Cr | β | β | 18.5% | 3.5% | 37.9% |
| Mar 2020 | βΉ376.00 Cr | β | βΉ29.00 Cr | β | β | 16.5% | 13.9% | 163.6% |
| Mar 2019 | βΉ330.00 Cr | β | βΉ11.00 Cr | β | β | 6.9% | -4.1% | -15.4% |
| Mar 2018 | βΉ344.00 Cr | β | βΉ13.00 Cr | β | β | 8.4% | 17.0% | -38.1% |
| Mar 2017 | βΉ294.00 Cr | β | βΉ21.00 Cr | β | β | 14.3% | 5.4% | 75.0% |
| Mar 2016 | βΉ279.00 Cr | β | βΉ12.00 Cr | β | β | 9.0% | 15.3% | 1100.0% |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 666 |
| Total Expenses | 517 |
| EBIT / Operating Profit | 149 |
| OPM % | 22% |
| Other Income | 139 |
| Finance Costs | 1 |
| Depreciation & Amortisation | 21 |
| Profit Before Tax | 267 |
| Tax % | - |
| Net Profit / PAT | 215 |
| EPS (βΉ) | 130.25 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| RPG Life Sciences Limitedthis co. | βΉ3.81 K Cr | βΉ653.00 Cr | 34.20 | 6.91 | 27.67 | 12.2% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |